Global Burkitt Lymphoma Therapeutics Market 2018-2022: Increasing Strategic Alliances in the Field of Oncology to be One of the Major Trends

DUBLIN, Sept 21, 2018 /PRNewswire/ --

The "Global Burkitt Lymphoma Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Burkitt Lymphoma Market to grow at a CAGR of 3.07% during the period 2018-2022.

Burkitt lymphoma market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Increasing strategic alliances in the field of oncology to be one of the major trends in the market vendors in the global oncology drugs market are regularly engaging in strategic alliances to strengthen their market position. Such alliances help these vendors consolidate their position and extend their geographical reach.

According to the report, one driver influencing this market is the rapid progression of Burkitt lymphoma requires immediate medical attention. Burkitt lymphoma is recognized as one of the fastest growing tumours in humans and is highly fatal if left untreated during the early stages.

Further, the report states that one challenge affecting this market is the high cost of the treatment. The chemotherapy drugs used in the treatment of Burkitt lymphoma are expensive. The high cost of chemotherapy drugs is one of the major challenges faced by the global Burkitt lymphoma therapeutics market.

Key vendors

• Biogen
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Novartis
• Spectrum Pharmaceuticals

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: DISEASE OVERVIEW

PART 05: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 08: PIPELINE

PART 09: MARKET SEGMENTATION BY DRUG CLASS

• Segmentation by drug class
• Comparison by drug class
• Biological - Market size and forecast 2017-2022
• Small molecule - Market size and forecast 2017-2022
• Market opportunity by drug class

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

• Geographical segmentation
• Regional comparison
• Key leading countries
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
  

For more information about this report visit

https://www.researchandmarkets.com/research/xddbjw/global_burkitt?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content to download multimedia:http://www.prnewswire.com/news-releases/global-burkitt-lymphoma-therapeutics-market-2018-2022-increasing-strategic-alliances-in-the-field-of-oncology-to-be-one-of-the-major-trends-300716941.html

SOURCE Research and Markets